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“All disease begins in the gut” 
Hippocrates (460-377 BC) 
 
“What gets measured, gets managed” 
Peter Drucker (1909-2005) 
 
“Seek and you shall find” 
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Background: Crohn's disease (CD) is a chronic inflammatory disorder in the 
gastrointestinal (GI) tract, characterized by alternating periods of remission and 
relapse. Patients’ symptoms do not reliably represent inflammatory activity and 
management should be based on objective evaluation. Currently, ileocolonoscopy is 
the established reference standard method for both diagnosis and monitoring disease 
activity in most cases, but holds several limitations restricting repeated use. 
Consequently, there is a need for safe, objective and accurate methods to measure the 
degree of inflammation and treatment response. Gastrointestinal ultrasound (GIUS) is 
a promising modality in assessing disease activity and may be a useful tool for aiding 
physicians improving treatment decisions.  
Aims: The primary objective of the PhD project was to examine the usefulness of 
ultrasound in evaluating disease activity in patients with Crohn’s disease. 
Specifically, we aimed to investigate the ability of Dynamic Contrast-Enhanced 
Ultrasound (DCE-US) to provide information of treatment effects (paper I), to assess 
the diagnostic accuracy of GIUS in separating endoscopic remission from active 
disease (paper II), and to construct and validate a simple ultrasonographic activity 
index to quantify disease activity (paper III).   
Material and Methods: In paper I, 14 CD patients receiving medical therapy due to 
an acute exacerbation were examined with conventional- and contrast-enhanced 
ultrasound at four time points. In paper II, 145 CD patients scheduled for 
ileocolonoscopy were prospectively examined with GIUS within 2 weeks prior to or 
after the endoscopic procedure. The Simple Endoscopic Score for Crohn’s disease 
(SES-CD) was used as a reference standard. In paper III, 164 patients scheduled for 
ileocolonoscopy were prospectively examined with GIUS, identically performed as in 
paper II. 40- and 124 CD patients were included in the construction- and validation 
cohorts, respectively.  
Results: In paper I, we found significant differences in relative perfusion between 
responders and non-responders one month after treatment start. As a secondary 
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finding, differences in bowel wall layers were revealed, where the proper muscle- and 
submucosal layers were significantly thicker in non-responders at one and three 
months after treatment initiation, respectively. In paper II, we found that bowel wall 
thickness measurements on GIUS had 92.2% sensitivity, 86% specificity and 90.3% 
accuracy in separating the disease status. By adding color Doppler in sections with 
increased wall thickness and fecal calprotectin in sonographic colitis, the diagnostic 
accuracy improved. In paper III, we developed a simplified ultrasound score 
consisting of bowel wall thickness and color Doppler. The ultrasound score correlated 
well with SES-CD in both patient cohorts (Development cohort: r=0.83, p<0.001, 
Validation cohort: r=0.78, p<0.001), and revealed excellent interobserver agreement 
(Development cohort: ICC=0.95.Validation cohort: ICC=0.90). 
Conclusions: We conclude that ultrasound is able to differentiate between patients 
with endoscopic remission and active disease, and a simple ultrasonographic scoring 
system is useful to evaluate the degree of endoscopic disease activity in CD. 
Furthermore, GIUS enables prediction of treatment effect shortly after treatment start, 
thus improving treatment decisions. 
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1.1 Crohn’s disease 
1.1.1 Background 
Inflammatory bowel disease (IBD) comprises two major disorders, ulcerative colitis 
(UC) and Crohn’s disease (CD) (1). All studies included in the thesis were performed 
on CD patients, mainly focusing on ultrasonographic characteristics and assessments 
of these patients.  
Crohn’s disease is a chronic inflammatory disorder affecting the gastrointestinal (GI) 
tract, characterized by an alternating course between remission and relapse. 
Transmural inflammation, skip lesion distribution, and several severe complications 
are other distinctive features of CD (2). The disorder is usually diagnosed in young 
adults, and consequently, patients are affected for years (3). The disease course varies 
between sustained quiescence in some patients to severe inflammation leading to 
serious complications necessitating surgical treatment in others (4). Due to the 
unpredictable course, individual adjustments of treatment and follow-up is 
mandatory.  
 
1.1.2 Epidemiology  
During the last decades, the incidence and prevalence of CD have been increasing 
worldwide (5, 6). Still, significant geographical differences exist, with higher 
frequency in western, industrialized countries (5-7). Further, higher incidence rates 
are reported in northern compared with southern latitudes in Europe (8) and North 
America (9), as well as an East-West gradient within Europe (7). In Norway, the 
incidence and prevalence of CD are 22/100 000 and 258/100 000, respectively (10).   
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1.1.3 Etiology  
Even though CD has distinctive pathologic and clinical traits, the pathogenesis 
remains poorly understood. Currently, the main hypothesis suggests that 
environmental factors trigger epithelial dysfunction on genetically susceptible 
individuals leading to an inappropriate immune response against the microbial flora, 
causing inflammation and tissue damage (2, 11, 12). To date, no single immune-
triggering environmental factor is identified, however, industrialization and adoption 
of western lifestyle are related to the increasing incidence of CD in developing 
countries (13). Smoking is the best documented risk factor associated with CD, but 
cannot explain the increased global incidence, suggesting multifactorial etiological 
triggers (13). 
 
1.1.4 Disease manifestation 
Patients are phenotypically categorized according to the Montreal classification (14), 
where age at diagnosis (<16 years (A1), 16-40 years (A2), and >40 years (A3)), 
location (ileal (L1), colonic (L2), ileocolonic (L3), and isolated upper disease (L4)), 
and behavior (inflammatory (B1), stricturing (B2), and penetrating (B3)) are 
characterized. Additionally, a perianal modifier (p) may be added when present 
(Figure 1). Where ulcerative colitis affects the colon in a continuous pattern, CD may 
affect the entire GI tract from the mouth to the anus in a skip pattern. Still, the 
majority of CD lesions are usually limited to the ileum and colon, where 
approximately 30% of CD patients present with ileal (L1), colonic (L2), or 
ileocolonic (L3) affection (3, 15). In contrast, approximately 5% present with upper 
disease (4). The disease location seems to remain stable, while the behavior varies 






Figure 1: Location and behavior categorized according to the Montreal classification.   
 
Clinical presentation varies due to differences in disease location, behavior, and 
activity. The intestinal inflammation may cause symptoms such as chronic diarrhea, 
possibly with blood or mucus, abdominal pain, and weight loss, as well as general 
symptoms such as fever, malaise, and fatigue due to systemic inflammation (2, 17). 
Most patients present with a non-stricturing/ non-penetrating behavior (B1) at the 
time of diagnosis (15, 16). As disease behavior changes over time, approximately half 
of the patients develop stricturing or penetrating complications (4, 18). Stricturing 
disease causing bowel obstruction could present as post-prandial abdominal pain, 
nausea, and vomiting (2). In penetrating disease, the development of fistulas or 
abscesses occur. The formation of a fistula enables penetration of luminal content 
throughout the intestinal wall into other bowel segments or organs, and the symptoms 
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depend on its location (2). Abscesses may present as fever and abdominal pain, and a 
tender abdominal mass may be palpated (19). Finally, extraintestinal manifestations 
affecting joints (arthritis and ankylosing spondylitis), skin (erythema nodosum and 
pyoderma gangrenosum), eye (uveitis) or liver (primary sclerosing cholangitis) (20) 
may further complicate the disorder.  
 
1.1.5 Disease course  
CD patients may be classified into four primary disease courses, suggesting that no 
single management plan will suit all patients and should thus be tailored to the 
individual’s needs (4, 21). In a population-based study in Norway, the investigators 
found that 43% of patients may have a mild disease course and do not require long-
term intensive therapy. Still, most patients are likely to alternate between remission 
and relapse (15, 21), and may benefit from early aggressive long-term management. 
Even though clinical activity may diminish over time in some patients, the rate of 
acute deterioration and development of complications is high during the first ten 
years after diagnosis, leading to a naturally progressive destructive disease course (4, 
15). Requirements for corticosteroids, high C-reactive protein (CRP) at diagnosis, 
smoking, early onset, and perianal disease are factors that may predict a disabling 
course and poor prognosis (15, 22-25). Even though CD might be debilitating, the 
overall mortality is not increased (26).  
Chronic transmural inflammation may cause excessive damage of the intestinal wall 
leading to fibrotic changes due to aberrant healing failing to restore normal tissue 
architecture (27, 28). Strictures occur in approximately half of all CD patients (27) 
and are subdivided into mainly fibrotic, inflammatory, or mixed types (29). 
Distinguishing between the various clinical expressions is important due to different 





Gross examination of resected specimens typically reveals bowel wall thickening, 
serosal fat wrapping (“creeping fat”), and longitudinal ulcers in a discontinuous 
pattern with a sharp demarcation to the adjacent uninvolved bowel (31). Severe 
inflammation could lead to the formation of penetrating complications such as 
fistulas, sinuses, or abscesses, which are mainly found in patients with ileal or 
ileocolonic involvement. Strictures are identified as stiff bowel segments with a 
narrowed lumen (31). 
By microscopic examination, discontinuous chronic inflammation, crypt irregularity, 
and non-caseating granuloma are histological features allowing for diagnosing CD. 
Moreover, muscular- and neural hypertrophy, increased neutrophilic infiltration into 
the epithelial layer, and proximal affection are additional histological features. 
Currently, no single diagnostic feature is available; still, the presence of granuloma 
together with one additional finding could establish the diagnosis (31). Although 
considered as the hallmark of histological diagnosis in CD, the presence of non-
caseating granulomas ranges from 20-60% of cases (32-34) and is more frequent in 
pediatric patients (32). Moreover, the formation of granuloma seems to be associated 
with aggressive phenotypes (33, 35) but may regress during treatment (34). Even 
though non-caseating granulomas are lacking in a substantial number of patients, the 
histological diagnosis could be established by other characteristic microscopic 
features (31). 
Several immune-mediated factors promote increased angiogenesis of the bowel wall, 
perpetuating chronic inflammation (36, 37). Moreover, impaired local tissue 
perfusion due to microvascular dysfunction creates an ischemic environment which 
may further sustain the inflammatory state and facilitate neovascularization (37, 38). 
Enhanced angiogenic activity due to neovascularization can be reflected by increased 
microvessel density and expression of vascular- and pro-inflammatory mediators (39, 
40). Furthermore, increased blood flow occurs in acute inflammation while it is 
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reduced in chronically inflamed segments (41). Hence, measurements and 
quantification of microvessel density and perfusion may aid evaluation of the degree 
of inflammation. 
 
1.1.7 Diagnostic modalities and indices 
Currently, no single gold standard method for CD exists. Both diagnosis and disease 
activity assessments are based on a combination of clinical, biochemical, 
radiological, endoscopic, and histological evaluations (42, 43).  
 
1.1.7.1 Clinical assessment  
Clinical assessment of CD patients is performed in both daily practice as well as in 
clinical studies. A structured medical history mapping clinical presentation, evolution 
of symptoms, risk factors, and general condition is commonly conducted. It is further 
accompanied by physical examination where cardiovascular status, calculation of 
body mass index, abdominal-, perianal- and digital-rectal examinations are performed 
(44). Clinical findings include identification of tender masses, palpable resistance, 
and abdominal pain by palpation, as well as fissures, fistulas, or abscesses during 
careful examination of the perianal region (17). Several scoring systems for 
measuring clinical disease activity are available, including the Crohn’s disease 
activity index (CDAI) (45) and the simpler Harvey-Bradshaw index (HBI) (46). The 
CDAI consists of a seven-day evaluation of eight clinical and laboratory variables. 
All variables are weighted, and finally, a total score is calculated. CDAI <150 is 
regarded as clinical remission, while 150-219 as mild, 220-450 as moderate, and 
>450 as severe disease activity (47). HBI is a simplified derivate of the CDAI, 
consisting of five clinical parameters. A HBI score of <5 represents clinical 
remission, while 5-7 is regarded as mild, 8-16 as moderate, and >16 as severe disease 
activity (47). The concordance between the indices is well-defined, where a change of 
3 points in the HBI corresponds to a 100-points change using the CDAI (48). 
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Improvements of clinical activity measurements are commonly used as endpoints in 
clinical trials, still, they do not sufficiently represent reliable measures of 
inflammatory activity (49, 50), and should be supplemented by objective markers.  
 
1.1.7.2 Biochemical evaluation 
 
Biochemical markers are used routinely in daily clinical practice for initial diagnosis 
as well as in follow-up examinations of IBD-patients (17), but specific tests are 
currently lacking. Common, but unspecific findings include general inflammatory 
markers such as elevated levels of CRP, erythrocyte sedimentation rate, leukocytes 
and thrombocytes (51), as well as low values of albumin (51) and hemoglobin due to 
chronic inflammatory activity or iron/vitamin deficiency (52). 
Stool samples can be analyzed for fecal biomarkers; Calprotectin is a neutrophil 
protein reflecting the migration of neutrophil leucocytes in the gut, representing a 
surrogate marker of bowel inflammation (53). Fecal calprotectin has higher 
diagnostic accuracy than CRP (54), correlates well with endoscopy (55), and is useful 
for disease activity monitoring (55, 56). Further, the biomarker is an accurate 
screening tool for IBD (57, 58), including exclusion of irritable bowel disease (IBS) 
(59). However, it seems better suited for evaluating activity in UC than CD (54), a 
lower accuracy is achieved in small-bowel compared to colonic CD (60), and it can 




Ileocolonoscopy is considered the reference standard method for both diagnosis and 
evaluation of disease activity in CD located in the colon and terminal ileum. It 
enables an excellent assessment of the mucosal surface and permits biopsy sampling 
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for histological evaluation. The presence of discontinuous lesions of aphthous, deep, 
stellate, linear, or serpiginous ulcers, stenosis, fistula, and cobblestoning of mucosa 
are typical endoscopic features of CD. Additionally, affection of the terminal ileum 
and perianal involvement further support the CD diagnosis (63). For activity 
monitoring and as an outcome measure in clinical trials, endoscopic activity indices 
are recommended (64). Crohn’s Disease Endoscopic Index of Severity (CDEIS) (65) 
was previously the only validated endoscopic activity score. However, the score is 
cumbersome and time-consuming, making the method unsuited for daily clinical 
practice. Consequently, the Simple Endoscopic Score for Crohn’s Disease (SES-CD) 
was developed (66). SES-CD correlates well with CDEIS (67) and may replace 
CDEIS in clinical trials as well as in routine work. Both scoring systems describe the 
rectum, left colon (descending colon and sigmoid), transverse colon, ascending colon, 
and the terminal ileum. The parameters included in the CDEIS-score are the presence 
of deep ulcers, superficial ulcers, surface involved by disease, ulcerated surface, 
ulcerated stenosis, and non-ulcerated stenosis. By using the SES-CD the size of 
ulcers, ulcerated surface, affected surface, and presence of stenosis are evaluated 
using a quantitative score of 0-3 per parameter per segment. The Rutgeerts score (68) 
is a scoring system developed for evaluation of post-operative recurrence of CD. 
Despite being recommended in international guidelines (69), no formal validation has 
been performed (63). Mucosal healing is absence of inflammation at endoscopy and 
has emerged as an important therapeutic goal in IBD (70). Even though consensus of 
endoscopic response and remission are recently established (71), there is currently no 
formally validated definition of mucosal healing (69). Common definitions of 
mucosal healing include SES-CD 0-2, CDEIS 0-3 (71), absence of mucosal 
ulcerations, or CDEIS/SES-CD = 0 (63). Despite numerous advantages of using the 
endoscopic quantitative indices to rate the severity of inflammatory activity, the 
complexity of the scoring systems limits their use in clinical practice (43).     
There are some major limitations using endoscopy. First, there is no knowledge 
whether inflammation persists in deeper layers of the bowel wall. Furthermore, most 
of the small bowel and peri-intestinal complications cannot be visualized (72). 
21 
 
Finally, the examination is invasive causing considerable patient discomfort (73) 




Due to the above-mentioned limitations of endoscopy, cross-sectional imaging 
modalities such as Ultrasound (US), Magnetic Resonance Imaging (MRI), and 
Computed Tomography (CT) are needed to provide complementary information. 
These imaging modalities have high and comparable diagnostic accuracies for initial 
assessment, follow-up examinations, and complications of the disease (42, 74-76). 
CT enterography is a fast and widely available imaging modality enabling detection 
of CD, as well as evaluation of disease activity, extent, and complications with high 
accuracy (77). Unfortunately, ionizing radiation exposure of CT represents a major 
disadvantage of this imaging modality. As repeated examinations increase the risk of 
cancer (78, 79) its use should be limited, particularly in young patients. Although 
ionizing hazards may be reduced using low-radiation-dose CT protocols (80, 81), 
non-ionizing imaging modalities are preferable in most clinical settings (42).    
MRI is a non-radiating imaging modality providing excellent visualization of a wide 
range of pathological features of CD, ideal for small bowel evaluation (42, 82-84). 
Due to the lack of ionizing radiation, the technique is well-suited for follow-up 
examinations and disease monitoring (85). Accordingly, MRI is the current standard 
for small-bowel assessment in CD (17). Disease activity may be quantified using 
dedicated scoring systems, where the MaRIA score may be most suitable (86). This 
validated activity index corresponds well with endoscopy to evaluate disease activity, 
severity (87, 88), and ulcer healing (89). Further, a simplified derivate of the activity 
index was recently developed (90), which may reduce the need for repeated 
ileocolonoscopies in activity monitoring. Although advocated as the preferred cross-
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sectional imaging modality, MRI is expensive, resource intensive, relatively 
inaccessible, and contraindicated in some patients (91).  
 
1.2 Ultrasound  
1.2.1 General  
Ultrasound (US) is high-frequency sound waves exceeding the upper audible limit in 
humans, capable of constructing greyscale images in real-time. Frequencies between 
2-15 megahertz (MHz) are commonly used in abdominal diagnostic imaging, and in 
contrast to X-ray modalities utilizing attenuation, ultrasonography is based on 
reflection of sound waves (92).   
Piezoelectric crystals inside the ultrasound transducer generate acoustic waves by 
transforming electrical voltage. The ultrasound waves are emitted inside the body and 
when reaching tissue boundaries, parts of the sound waves are reflected towards the 
probe, enabling conversion of ultrasound waves to electrical voltage, finally creating 
a grey-scale image (93). 
Sound waves are characterized by the frequency (f), wavelength (λ), and speed of the 
sound (c). The frequency is defined as the number of oscillations per second and has 
the unit of Hertz (1 Hertz = 1 cycle per second). The wavelength is referred to as the 
distance between two identical, consecutive coordinates on the waveform and has the 
unit of millimeters (mm). The speed of the sound has units of meter/second (m/s) and 
is determined by tissue characteristics ranging from 331 m/s in air to 3500 m/s in 
bone (93). However, an average of 1540 m/s is commonly used as the differences 
between most soft tissues are negligible (93). The relationship between frequency, 
wavelength, and speed is given by the formula:  
λ=c/f     (1)   
Since the propagation speed is treated as constant, optimization of the image is 
determined by the inversely related wavelength and frequency parameters. By 
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increasing the frequency, a higher resolution of the US image at the expense of depth 
penetration is obtained. Conversely, lower frequencies increasing the wavelength are 
chosen for appropriate visualization in structures that are deeply located.  
 
1.2.2 B-mode 
In Brightness mode (B-mode) imaging, the reflected US waves are displayed as dots 
of varying brightness proportional to the amplitude of the return echo, positioned 
according to the corresponding depth of the interface reflector. The final B-mode 
image is a combination of all returned echoes registered along the scan lines of 
multiple piezoelectric crystals inside the US transducer (92).  
 
1.2.3 Doppler 
Doppler ultrasound enables evaluation of the circulation by utilizing the Doppler 
Effect, defined as a change in frequency between the reflected- and emitted US wave, 
due to relative motion between the observer and the reflector (93). The Doppler effect 
(Δf) created by moving erythrocytes enables blood flow velocity (v) measurements, 
as expressed by the equation:   
           v = 
C · Δ𝑓
2𝑓0·cosθ
           (2) 
  
Further, knowledge of the ultrasound speed (C), frequency of the transmitted US (f0), 
and the cosine of the angle between the US beam and direction of blood flow (cosθ) 
are needed for performing the calculation.  
Color Doppler sonography enables evaluation of vessel patency as well as blood flow 
directions, where flow towards and away from the probe usually are coded as red and 
blue, respectively. Further, increased color intensity correlates with elevated flow 
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velocity, while a mosaic of colors may be seen in turbulent flow (94). Power Doppler 
sonography merges each frequency shift in the sampling volume, thus lacking the 
ability of flow direction assessments. The amplitude of reflected signals correlates 
with the number of erythrocytes regardless of velocity, hence, the sensitivity of small 
vessel detection increases (94).       
 
1.2.4 Contrast-enhanced ultrasound 
Doppler ultrasound is a well-established method to detect high-velocity blood flow; 
however, the availability for evaluating perfusion in organ parenchyma is limited due 
to lower velocities, making it difficult to discriminate blood flow from tissue motion. 
Contrast-enhanced ultrasound (CEUS) combines conventional ultrasound with 
ultrasound contrast agents (UCA), enabling evaluation of the microvasculature (95-
97). The role of CEUS is well-established in liver imaging (98), and several new 
applications have emerged during the last decades (99, 100).  
 
1.2.4.1 Ultrasound contrast agents   
 
Ultrasound contrast agents (UCA) are microbubbles consisting of a gas-filled core 
encapsulated by a biocompatible shell. The microbubbles are made small enough to 
pass capillary beds and no extravasation of contrast agents occurs, thus acting as a 
true intravascular tracer (101). Renal monitoring is usually unnecessary as the UCA is 
eliminated through the lungs (102, 103). 
Commercially available UCAs containing coated air bubbles were introduced in the 
nineteen nineties (104). Currently, second-generation agents containing biologically 
inert high molecular weight gases are chosen due to improved backscattering abilities 
as well as prolonged lifetime. In Europe, Sonovue (Bracco, Milan, Italy), a sulfur 
hexafluoride filled microbubble, is the most commonly used UCA.  
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Due to high compressibility of the UCA the bubbles contract and expand in response 
to the application of low energy ultrasound with appropriate resonance frequency, 
while in contrast, the surrounding tissue is relatively incompressible. Also, distorted 
non-linear reflections are produced, which can be differentiated from tissue-derived 
signals. The oscillation frequency of the microbubbles is inversely related to its size 
and the frequency of the US beam (101, 105), hence, higher doses of contrast agents 
are required to compensate size-frequency dissonance (106). When exposing the 
UCA to higher intensities, the coating shell disrupts due to rarefaction forces (high 
MI), releasing the encapsulated gas (101, 107).  
Various techniques have been developed to discriminate between non-linear UCA 
reflections and tissue-derived signals. In the pulse-inversion technique, two pulses of 
US with inverted phases are transmitted. The tissue-derived inverted linear echoes are 
summed thus canceling each other out, while in contrast, non-linear reflections from 
the microbubbles amplify each other when summed (101, 107, 108). In amplitude 
modulation, two US pulses with altered amplitudes are transmitted. Linear echoes are 
canceled out by subtracting the reflected pulses, while non-linear UCA-derived 
signals at various frequencies remain (107, 109). Modern US scanners most 
commonly combine phase inversion and amplitude modulation.  
 
1.2.4.2 Perfusion estimates  
 
Contrast-enhanced ultrasound (CEUS) enables quantification of the microvasculature 
(110, 111) due to a directly proportional relationship between the backscattered signal 
intensity and the microbubble concentration (112). Further, the analysis of contrast 
enhancement over time, dynamic contrast-enhanced ultrasound (DCE-US), enables 
estimation of perfusion (95, 113). The UCA remains intravascular, which is necessary 
for accurate perfusion measurements (95). There are currently two established 
administration methods, Bolus tracking and Burst replenishment (95, 114), yielding 
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different measurements. The preferred method depends on study purpose or clinical 
experience. Currently, the Bolus tracking technique is used more frequently than 
Burst replenishment in non-cardiac applications (95). 
In Bolus tracking, the contrast agents are administered as a bolus injection through a 
peripheral vein and after passing through the pulmonary circulation, the microbubbles 
reach the systemic circulation and the region of interest in the arterial phase. Finally, 
the contrast intensity gradually diminishes in the venous phase. Time-intensity data is 
detected during the arterial phase, where the arrival of UCA and decline in contrast 
enhancement is registered. By using appropriate software, the time-intensity data is 
fitted to a standardized curve from which several relative perfusion parameters are 
derived (95, 113).  
Perfusion quantification analyses are commonly performed on log-compressed 
versions of the actual ultrasound intensities. However, the only mathematically valid 
method is by using linear echo power data (115), which is proportional to the bubble 
concentration. Due to difficulties in obtaining linear raw data, re-linearizing 
conversion algorithms are available in modern quantification software applications 
(113), which is an acceptable alternative if the gain is properly adjusted and the 
dynamic range of log-compression exceeds 45 decibel (116).  
 
1.2.5 Safety 
Ultrasound is considered a safe modality with no proven harmful effects. Still, 
precautions should be made as sustained exposure with high power output produces 
heating and pressure changes in tissues which may be potentially hazardous (117).  
Heating occurs when energy from a propagating ultrasound wave is absorbed and 
converted to heat. An elevated temperature may affect normal cell functions, still, 
evidence of clinically significant deleterious effects is lacking (117). For guidance, an 
estimate of the temperature rise displayed as a thermal index (TI) is provided (93).  
                                                     TI=W/Wdeg             (3) 
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W=the power exposing the tissue, Wdeg=the power necessary to raise the temperature 
by 1oC. In presence of bones, an increased heating effect occurs due to higher 
absorption of US waves, thus, three versions of TI may be provided: soft tissue (TIS), 
bone at focus (TIB), and cranial (bone at surface) (TIC) (93).  
Pressure changes caused by compression and rarefaction of propagating ultrasound 
waves may lead to mechanical disturbances in tissues. High acoustic pressures could 
potentially induce unfavorable inertial cavitation, thus, a mechanical index (MI) 
estimating the likelihood of such induction is provided (93). 
MI=Pr/√f    (4) 
Pr= the peak rarefaction pressure, f= ultrasound frequency. 
Owing to the potentially deleterious effects of ultrasound, the thermal and mechanical 
indices are mandatorily displayed on ultrasound scanners. The As Low As Reasonably 
Achievable (ALARA)-principle is generally recommended, where TI >6 in adults and 
>3 in obstetrics, as well as MI >1.9, should be avoided (118, 119).  
Sonovue has a good safety profile with few and mild side effects, however, rare cases 
of serious adverse reactions have been reported in the literature, and emergency 
precautions should be taken (120-124). 
 
1.2.6 Ultrasonographic features of Crohn’s disease  
Ultrasound is non-invasive, cost-effective, well-tolerated by patients and can be 
performed bedside, making it well suited for repeated examinations. The impact of 
gastrointestinal ultrasound (GIUS) has increased significantly during the last decades, 
and dedicated GIUS-guidelines have recently been provided (125, 126). Due to 
logistic, safety, and economic reasons, ileocolonoscopy, CT, and MRI cannot be 
performed on a regular basis, and consequently, GIUS might be a useful supplement 
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in IBD management. A recent appraisal of the literature revealed good accuracy of 
US in diagnosis and mapping of complications, while poor and limited evidence was 
found for disease activity assessments (127). Previous meta-analyses show that there 
is a good correspondence between US, CT, and MRI in detection of the disease and 
complications as well as evaluating the extent and severity of the disease (74, 75). 
However, in light of recent technological advances of all modalities, updated meta-
analyses are warranted.   
Both low- and high-frequency probes are required to perform a thorough GIUS 
examination. A low-frequency curvilinear transducer provides good depth 
penetration, ideal for overview, identification of gross pathology as well as the 
examination of the deeply located rectum. A detailed examination of the distal ileum 
and colon is performed by systematic scanning from the terminal ileum and further 
distally, using high-frequency linear probes. Most of the small bowel is difficult to 
track due to a tortuous course, thus, a systematic four-quadrant examination is 
recommended. Then, the dorsal abdominal wall should be identified to ensure that all 
bowel segments are included in the scanning area. No preparation of the patient is 
required, but it is recommended that patients fast for at least four hours to reduce 
intestinal gas (125). 
Normally, the intestinal wall is less than two mm measured by ultrasound (128), and 
by using high-frequency probes, five to nine wall layers can be delineated depending 
on the transducer frequency. There are clear correlations between the wall layers 
revealed by ultrasound and histology (Figure 2), even though slight differences occur 




Figure 2: B-mode image of the author's healthy bowel. Five demarcated layers correspond 
partly to the intestinal wall layers. In practice, the hypoechoic layer 2 corresponds to the 
mucosa, whereas the hyperechoic layer 3 correlates with the submucosa, the hypoechoic 
layer 4 to the proper muscle, and the hyperechoic layer 5 to the serosa. The hyperechoic 
layer 1 corresponds to the interface between the mucosa and intestinal lumen. 
 
Increased bowel wall thickness (BWT) is the most common and important parameter 
for detecting CD (42, 126) (Figure 3), yielding high sensitivity and specificity (130, 
131). A recent meta-analysis showed that wall thicknesses exceeding three mm yield 
sensitivity and specificity of 89% and 96%, respectively. By increasing the threshold 
to four mm or higher, a sensitivity of 87% and a specificity of 98% were found. 
(131). Additionally, BWT may be useful in evaluating disease activity (132, 133), 
detection of postoperative recurrence (134) and prediction of surgery (135). Until 
recently (125) international guidelines regarding BWT measurements were lacking. 
Standardization of BWT assessment appears a prerequisite for high interobserver 
agreement (136), as inadequate instruction has resulted in poorer agreement rates 
even when performed by expert sonographers (137).  
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Figure 3: A thickened bowel wall (demarcated by yellow calipers) with normal stratification 
in a patient with Crohn’s disease. 
 
Echo patterns may differ in CD, ranging from preserved stratification and thickened 
submucosal layer (138, 139) to abrogation of the wall layers. Focal loss of bowel wall 
stratification is associated with ulcerations (140) (Figure 4), while diffuse disruption 
may be caused by severe transmural inflammation (126, 141), increasing the risk of 
surgery (142). In contrast, intact stratification and thickening of the proper muscle 
layer are indicative of fibrosis (139, 141). Moreover, a fibrofatty proliferation of the 
surrounding mesenteric fat is commonly present in patients with disease activity 
(143). It typically presents as echo-rich tissue encircling the affected bowel segments 
(Figure 4), however, a hypoechoic appearance may be seen in long-standing disease 
(144). Other common, but unspecific extraintestinal findings include enlarged 






Figure 4: The left panel shows a focal loss of stratification (arrow), while the image in the 
right panel displays inflammation in the mesenteric fat (fatty wrapping) (arrow). 
 
Several complications of CD can be detected by US. Intestinal stenosis appears as a 
segmental increase in bowel wall thickness with a narrowed lumen and prestenotic 
dilatation exceeding 2.5 cm (Figure 5), often accompanied by hyperperistalsis. 
Fistulas are visualized as hypoechoic tracts between intestinal loops and other tissues. 
In addition, content of air bubbles seen as hyperechogenic structures within the duct 
may be present. Abscesses usually appear as irregular hypoechoic peri-intestinal 
structures, containing echo-rich air bubbles (126, 145).  
 
 
Figure 5: Stenosis in the terminal ileum with prestenotic dilatation.  
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In active CD, increased angiogenesis featuring neovascularization and local 
dysregulation of the blood supply is present (38, 39), allowing for quantification of 
the microvasculature as a means of activity assessments. Color Doppler 
measurements of the GI wall enables differentiation between active and inactive 
disease and correlates with endoscopy, histology, and CDAI (146-151) (Figure 6), 
and there is a negative correlation between Doppler signals and fibrosis (152). 
Furthermore, color Doppler measurements may aid physicians to monitor disease 
status and evaluate treatment effect (132, 133). However, color Doppler has limited 
resolution for small vessels with low-velocity blood flow (153), possibly making the 
modality less sensitive for microvascular changes. 
 
Figure 6: A bowel loop with increased color Doppler signals is depicted in longitudinal- and 
transverse sections in the left and right panel, respectively. 
 
Previous meta-analyses revealed that CEUS is well-suited for detection of active CD 
with high sensitivity and specificity (154, 155), although affected by significant 
heterogeneity between the included studies. Disease activity evaluation may be 
performed using semi- (156, 157) or quantitative methods (151, 158-163), where 
increased contrast enhancement corresponds to inflammation. Further studies suggest 
that CEUS might be useful in differentiating between inflammatory and fibrotic 
lesions, where low values of relative signal intensities (152, 164-166) and absolute 
perfusion parameters indicate fibrosis (139). In addition, early evaluation of CEUS-
derived perfusion parameters may be useful in determining treatment outcome, thus 
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enabling improvements of management (167-169). The main application of CEUS in 
clinic, however, is to differentiate between abscesses and phlegmons (Figure 7) (99, 
170).  
Figure 7: Ultrasound images of an abscess. The B-mode image in the left panel displays a 
hypoechoic lesion (arrow). The corresponding contrast image in the right panel shows a 
hypoechoic central structure with contrast enhancement in the peripheral zone.  
 
In the treat-to-target era, reaching objective endpoints are favorable as beneficial 
changes in the disease course are provided. Mucosal healing has emerged as the main 
therapeutic target, but endoscopy fails to detect persistent inflammation in deeper 
layers in transmurally affected bowels. Hence, transmural healing defined as 
normalization of the bowel wall at cross-sectional imaging may be a more appropriate 
treatment goal (171). Studies report that sonographically measured transmural healing 
correlates well with mucosal healing but seems harder to achieve (163, 172-174) and 
may represent a more profound level of healing. In a recently published retrospective 
study, transmural healing measured by ileocolonoscopy and MRI-enterography was 
found to be superior in any outcome compared to mucosal healing alone (175). Still, 
the clinical role of transmural healing remains to be determined (171, 176).  
In the hands of trained clinicians, GIUS substantially improves clinical decision 
making (177) and is useful for activity monitoring (132). Suitable scoring systems for 
measuring inflammatory activity are available for several diagnostic modalities (43). 
 34
However, the methodology for development is inadequate in most ultrasound indices 
(178).  
 
1.3 Treatment of Crohn’s disease 
Inflammatory lesions of CD are treated medically with topical or systemic steroids, 
immune modulators, and biologics, while endoscopic dilatation or surgical resection 
is performed in fibrotic segments (17, 27, 30, 179). Appropriate management depends 
on accurate determination of disease activity, site, and behavior. The traditional 
approach of CD management is based on alleviation on patients’ symptoms using a 
“step-up” strategy, starting with less potent medication and further escalation if 
inadequate effect (180). However, due to mismatch between symptoms and disease 
activity, persistent subclinical inflammation may go undetected, ultimately leading to 
irreversible bowel damage (4, 181). Thus, a new management paradigm has emerged 
treating beyond clinical symptoms to objective endpoints, where mucosal healing is 
considered as the main therapeutic target (182). Acquiring mucosal healing is 
correlated with less hospitalization, relapse rates, surgery, and bowel damage (70, 
183-186), and may be key to change patient outcomes (187, 188). Further evidence 
suggests that a better optimization of therapy may be achieved when based on 
objective markers of inflammation rather than on symptoms alone (189). Topical or 
systemic steroids are recommended to induce remission in CD, with further 
escalation to immunosuppressants when necessary (17, 179). Still, a “top-down” 
strategy with early introduction of biologics may be appropriate in patients with 
severe disease or poor prognostic factors (179, 190). Unfortunately, some patients 
have suboptimal response to biologics or experience drug failure over time (191, 
192). Furthermore, these drugs are expensive and have potentially serious side effects 
(193). Consequently, frequent follow-up examinations using simple, accurate tools 
for objective evaluation of disease status are needed for improved treatment 
management.    
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2. Rationale and aims  
2.1 Rationale  
Many CD patients suffer significantly due to impaired bowel function. Affected 
individuals are usually diagnosed of young age, thus numerous follow-up 
examinations are needed to evaluate disease activity and treatment effect. Due to a 
mismatch between patients’ symptoms and the degree of disease activity, there is a 
need for objective measurements of the degree of inflammation in the intestinal wall 
in order to improve management. Gastrointestinal ultrasonography is potentially 
useful for evaluating changes in disease activity in affected bowel segments and may 
thus be a useful recourse in facilitating patient care.   
 
2.2 Aims  
The principal aim was to investigate the ability of ultrasonography to assess disease 
activity in patients with CD. The thesis is based on three papers, with each specific 
objective:  
I. To evaluate whether DCE-US-derived perfusion parameters can be used to 
monitor disease activity and treatment effect in patients with CD. Secondly, 
we aimed to investigate the most appropriate time to perform the follow-up 
examinations. 
 
II. To assess the diagnostic accuracy of GIUS in separating CD patients in 
endoscopic remission from patients with active disease.  
  
III. To construct, validate, and assess interobserver agreement of a simple 
ultrasonographic scoring system for evaluation of disease activity in CD.  
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3. Materials and methods 
3.1 Study population  
In paper I, 14 CD patients (nine men) scheduled for treatment with either 
corticosteroids or biologics due to disease flare-up (defined as CDAI > 150 points) 
were prospectively recruited from the outpatient clinic or at the ward at the Section of 
Gastroenterology at Haukeland University Hospital, Bergen, Norway. All patients 
completed four follow-up examinations during 12 months. 
In paper II and III, we prospectively included 145 (58 men) and 164 (66 men) 
patients, respectively, who were referred to ileocolonoscopy as part of standard care 
at the Department of Medicine at Haukeland University Hospital, Bergen, Norway, 
(Paper II and III) and the Department of Medicine at Ålesund Hospital, Norway 
(Paper III). All study participants in paper II were also included in paper III. 
A detailed description regarding inclusion and exclusion criteria are provided in the 
associated papers.  
 
3.2 Study design and enrolment 
All studies were observational. The ileocolonoscopic examinations, decision-to-treat, 
or changes in medical therapy were performed as part of usual care.  
Paper I was designed as a prospective follow-up study, examining patients at four 
time points (treatment start, and one, three, and twelve months after). The first US 
examination was performed within 3 days after treatment start. Study outcomes were 
clinical remission (defined as CDAI<150 after 12 months of treatment start) and 
treatment failure (defined as a change in medical therapy > 1 month after treatment 
start) during the follow-up period.  
Paper II and III were designed as prospective cross-sectional studies, comparing the 
diagnostic accuracy of GIUS in predicting and quantifying endoscopic activity. All 
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patients were examined with US within two weeks before or after the 
ileocolonoscopy.  
 
3.3 Ethical permissions 
The Regional Ethics Committee for Medical and Health Research in Western Norway 
(REC West) approved all studies (REC West nos. 22209 (study I) and 2017/1750 
(study II and III)). Studies II and III were reported to ClinicalTrials.gov ID: 
NCT03481751. Each study was performed in accordance with the Declaration of 
Helsinki. All patients gave written informed consent prior to participation. 
 
3.4 Clinical assessment 
Patient demographics, past medical history, and phenotype according to the Montreal 
classification (Appendix I) were obtained through patient anamnesis or, upon 
consent, access to the medical records. The Crohn’s Disease Activity Index (CDAI) 
was used to evaluate clinical disease activity in paper I. However, the CDAI is 
complex and cumbersome to use, requiring a seven-day patient diary making it prone 
to recall bias. Therefore, Harvey Bradshaw Index (HBI) was used in paper II and 
III, enabling a simpler calculation of clinical disease activity. CDAI and HBI are 
presented in appendix II and III, respectively.  
 
3.5 Biochemical analysis 
Blood and stool samples were obtained within one week prior to, after, or on the 
same day as the US examination in all papers. Hemoglobin (g/dL), leucocyte count 
(109/L), platelet count (109/L), CRP (mg/L), erythrocyte volume fraction, and 
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albumin (g/L) were analyzed from blood samples, while fecal calprotectin (mg/kg) 
was measured from stool samples. All biochemical samples were analyzed at the 
laboratory facilities of Haukeland University Hospital (paper I-III) and Ålesund 
Hospital (paper III).    
 
3.6 Reference standard  
In paper I, CDAI was used as reference standard for assessing disease activity where 
a CDAI score exceeding 150 points was considered as active disease, while a CDAI 
<150 points was defined as clinical remission. Decision to treat was based on a 
clinical consensus. In paper II and III, the Simple Endoscopic Score for Crohn’s 
Disease (SES-CD) evaluated by ileocolonoscopy was used as reference standard. 
Endoscopic remission was defined as a SES-CD score of 0 and 0-2 in paper II and 
III, respectively. The SES-CD is presented in appendix IV. 
 
3.7 Ultrasound methods  
3.7.1 Ultrasound scanners and probes  
A GE Logiq E9 high-end scanner (GE Healthcare, Milwaukee, USA) was used in all 
studies. The ultrasound scanners were equipped with low-frequency curvilinear 
probes (C1-5/C1-6, 1-6 MHz) and high-frequency linear transducers (9L, 5.5-9 MHz, 
and ML6-15, 9-15 MHz). The CEUS examinations were performed using a high-
frequency linear probe (9L, 5.5-9 MHz). Further details regarding US equipment are 
provided in the enclosed papers.  
 
3.7.2 B-mode examination  
In all papers, the settings of frequency, focus, and gain were optimized until the best 
images were obtained. Each patient was examined with a low-frequency curvilinear 
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probe for overview and a linear transducer for a detailed examination of the bowel 
wall. Ultrasound scanning was performed as previously described (125, 145). In 
short, the large bowel was examined by scanning systematically from the terminal 
ileum and further distally in longitudinal section. As the remaining part of the small 
bowel is difficult to track, a systematic scanning of the four abdominal quadrants 
aiming for target lesions was performed. The examination of the rectum was 
performed using the convex probe as it is deeply located. All bowel wall thickness 
measurements were performed in the anterior wall in longitudinal section. Wall 
thickness was measured from the interface echo between the serosa and the proper 
muscle to the interface echo between the mucosa and the lumen, and two and three 
representative measurements were averaged in paper II-III and I, respectively.  
In paper I, pathological wall thickness was defined as >2 mm if the bowel lumen 
diameter was >0.5 cm and >3 mm if the lumen diameter was <0.5 cm or collapsed. 
Additionally, the thickness of individual wall layers was measured. In paper II and 
III, pathological wall thickness was defined as >3 mm.   
The length of the affected segments was measured in paper I and III. In paper II 
and III, color Doppler measurements were recorded and quantified in segments with 
pathological wall thickness. Moreover, focal or entire disruption of bowel wall 
stratification and the presence of fatty wrapping were evaluated in paper III. Finally, 
the presence of stenosis and fistulas were recorded during the first part of paper III. 
Further definitions and score characteristics of the ultrasound variables are presented 
in appendix V. 
 
3.7.3 Doppler examination  
In paper II and III, color Doppler was performed on bowel segments exceeding 3 
mm. Doppler settings were adjusted for optimal registration of low blood flow 
velocities. The velocity scale was reduced to 5 cm/s while gain was increased until 
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flash artifacts occurred and then lowered until they disappeared. The acquisitions 
were performed during patient breath-hold to reduce motion artifacts. Color pixels 
were interpreted as vessels if they persisted during the observation period. Bowel 
wall vascularity was evaluated semi-quantitatively by counting the number of 
Doppler signals per cm2 using a modified version of (150), where 0-1, 2-5, and >5 
signals were scored as 0, 1 and 2, respectively (appendix V).  In paper II, a Doppler 
score of 0 was interpreted as remission, while activity was defined as a Doppler score 
of 1-2. 
 
3.7.4 Software for interobserver assessment  
In paper III, still images and cine loops of patients included in the development 
cohort were reviewed by another examiner to assess interobserver reproducibility of 
the chosen sonographic parameters. The software evaluation was performed on the 
development cohort before including the validation cohort. We used two offline 
software applications: Phillips DICOM Viewer (Phillips Medical Systems, Best, The 
Netherlands) and Onis® (DigitalCore, Co. Ltd, Tokyo, Japan). The application from 
Phillips was used for most purposes due to its simplicity and reliability, while the 
evaluation of Doppler signals was performed using the Onis viewer as it enables 
measurements of cm2. 
 
3.7.5 Contrast-enhanced ultrasound  
In paper I, we performed contrast-enhanced ultrasound. In the study preset, the 
Logiq E9 uses amplitude modulation to register UCA backscattering. General 
contrast settings were selected, the gain adjusted to reduce tissue-derived signals, and 
the MI was set to 0.09-0.12 to prevent bubble destruction. Sonovue (Bracco, Milan, 
Italy) was used as UCA in all examinations.  
A peripheral venous catheter of 20 gauge (1.1 mm) was inserted in the left cubital 
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vein, through which the UCA was administered. The contrast-injection was 
performed by a hospital nurse instructed beforehand. The anterior wall at the thickest 
section observed during the B-mode scan was examined with CEUS in longitudinal 
view.  
The CEUS examination was performed using the Bolus tracking technique. In each 
patient, two contrast injections were performed consecutively, and 60-second 
acquisitions were made over the right iliac artery and the affected bowel loop. The 
CEUS data was saved as a Digital Imaging and Communications in Medicine 
(DICOM) file. Further details of the CEUS-examination are described in the 
corresponding paper.  
 
3.7.6 Software for perfusion analysis  
The CEUS data was evaluated, re-linearized, and quantified using a commercially 
available software application, VueBox® (Bracco Suisse SA, Geneva, Switzerland, 
version 4.2), as described in paper I. The program fits the time-intensity data to a 
standardized curve from which different perfusion parameters are derived.  
 
However, most perfusion parameters are presented as arbitrary units, relative to the 
actual perfusion. To solve this issue, we performed a scaling procedure of the bowel 
parameters using the right iliac artery as an internal reference. The time-related 
parameters are not influenced by the concentration of the UCA (194), making the 
scaling procedure unnecessary.  
 
Three parameters were excluded before final analysis; Time of arrival and time to 
peak are significantly influenced by the arterial input factor (AIF) and were thus 
avoided. The wash in perfusion index is calculated from other parameters and does 
not provide additional information.  
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3.8 Statistics  
All statistical analyses were performed using Statistical Package for the Social 
Sciences (SPSS) (IBM, Inc Armonk, NY), version 20 and 25 for paper I and II-III, 
respectively.  
Demographical data are presented as median, minimum, and maximum values in all 
studies. The distribution of the data set was evaluated by inspecting histograms and 
boxplots as well as using the Shapiro-Wilk test. For continuous data, comparison 
between patient groups was performed using Student’s t-test if normally distributed, 
and Mann-Whitney U test if not. For categorical data, the Chi2-test or Fischer exact 
test were used. Spearman’s rank was used to describe the correlation between 
different variables.  
In paper II, the diagnostic accuracy of GIUS and clinical- and biochemical tests were 
expressed by sensitivity, specificity, positive predictive value, negative predictive 
value, and total accuracy. Furthermore, kappa statistics were used to evaluate inter-
rater reliability as well as to investigate the agreement between ileocolonoscopy and 
clinical- biochemical- and ultrasonographic variables.  
In paper III, multiple linear regression was performed to select which ultrasound 
parameters that should be included in an ultrasonographic scoring system. 
Spearman’s rank and intra-class correlation (ICC) were used for assessing inter-rater 
correlation and agreement, and limits of agreement and assessment of potential biases 
between the investigators were evaluated using Bland-Altman analysis. Furthermore, 
a receiver operator curve analysis was performed to identify suitable cut-offs for 
separating remission and activity.  
The level of significance was P<0.05 in all papers. Further details regarding statistics 
and data handling are presented in the included papers.       
43 
 
4. Summary of main results  
4.1 Paper I 
14 patients were included of which six had treatment failure during the follow-up 
period. At 12 months, 11 patients were in clinical remission, two patients had active 
disease, and one patient underwent surgery. There were no statistically significant 
differences between the treatment failure and effective treatment groups in 
demographics, clinical- or biochemical data at any time point.    
 
We found significant differences in some amplitude-related perfusion parameters one 
month after treatment start: peak enhancement (p=0.013), wash-in area under the 
curve (p=0.013), wash-in rate (p=0.020), and wash-out rate (p=0.008). These 
differences occurred before changes in any treatment was done. There were no 
significant differences for the remaining amplitude-related parameters at one month 
(wash-out area under the curve (p=0.142) and wash-in/ wash-out area under the curve 
(p=0.059)), or at the other time points during follow-up (at 0, 3 and 12 months). The 
time-related parameters were statistically insignificant at each time-point.  
 
There were no significant differences in BWT or length of the affected segments at 
any time point. However, we found significant differences in bowel wall layers, 
where the proper muscle- and submucosal layers were significantly thicker in non-
responders at one and three months after treatment initiation, respectively. 
 
4.2 Paper II 
102 patients had active disease and 43 patients were in endoscopic remission. There 
were significant differences between the groups in disease behavior and previous 
surgery, as well as for HBI, CRP, and calprotectin.   
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A bowel wall thickness (BWT) exceeding 3 mm provided a sensitivity and specificity 
of 92.2% and 86% to distinguish between patients with inflammatory activity and 
patients in remission. Corresponding values for color Doppler were 66.7% and 
97.7%, respectively. Moreover, BWT (r=0.69, p<0.001) and color Doppler (r=0.64, 
p<0.001) correlated well with SES-CD. Furthermore, an interobserver analysis of a 
subset of the included patients (n=23) revealed excellent agreement between the 
investigators for both BWT (k=0.90) and color Doppler (k=0.91) measurements. The 
diagnostic accuracy of ultrasonography significantly exceeded the corresponding 
values for clinical- and biochemical tests.  
False negative results (n=8) were due to aphthous lesions in the terminal ileum in five 
cases (SES-CD=3), aphthous lesions and edema in the terminal ileum (SES-CD=6) 
were present in one case, while two cases revealed erythema and faded vascular 
pattern in the colon (SES-CD=1 and 6). Six false positive results were present in both 
colon (n=2) and the terminal ileum (n=4). By adding fecal calprotectin in isolated 
colonic thickening, all patients were correctly classified.  
 
4.3 Paper III 
A total study population of 164 were prospectively included, of which 40 and 124 
were included in the development and validation phases, respectively.  
Due to significant multicollinearity between BWT and length as well as no cases of 
fistulas, we excluded the latter two parameters. The combination of the remaining 
parameters provided the highest multiple correlation coefficient (r=0.78), but the 
predictive value of the ultrasound score was not reduced after excluding stenosis.  
By re-examining the development cohort, we found good to excellent agreement 
between the investigators for calculating the score (ICC=0.93), as well as for BWT 
(ICC=0.91) and color Doppler (ICC=0.94). However, a poorer agreement was 
revealed for evaluating stratification (ICC=0.60) and fatty wrapping (ICC=0.45). 
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There were no fixed or proportional biases between the investigators in assessing the 
activity index and its components.  
BWT and color Doppler were the only parameters with unique significant 
contributions to the model, and they achieved high interobserver reliability. Thus, we 
therefore simplified the ultrasound score by excluding stratification and fatty 
wrapping. The remaining activity index correlated well with SES-CD (r=0.83, 
p<0.001) and had high reproducibility (ICC=0.95) 
The simplified ultrasound score correlated well with ileocolonoscopy (r=0.78 
p<0.001) in the validation cohort, while poorer correlations were revealed for 
clinical- and biochemical tests. 23 patients were independently examined by two 





5.1 Methodological considerations  
In paper I, we used the CDAI as reference standard as it is commonly employed to 
define clinical endpoints in trials. Still, assessment of clinical disease activity remains 
challenging as patients' symptoms do not reliably measure underlying inflammation 
(49), and current treatment goals have shifted from alleviation of symptoms to 
objective endpoints. Although developed for measuring disease activity in CD, 
similar CDAI scores may be present in patients with Irritable Bowel Syndrome (IBS) 
(195), and due to a considerable coexistence of IBS in CD patients (196), the ability 
of clinical scores to distinguish between active CD and other conditions is limited. 
However, the decision to treat and changing treatment regime was performed as part 
of standard care by the treating physician unaware of the ultrasound results.  
 
Ultrasound is operator-dependent, and the investigator’s level of experience may 
significantly impact the quality of the results. All CEUS-acquisitions were obtained 
by an experienced sonographer in paper I, while the primary investigator conducted 
the perfusion analyses and was at that time a medical student with little experience in 
clinical ultrasound. Despite some training in bowel ultrasonography and instructions 
on how to use the quantification software, the lack of experience might influence the 
validity of the results. Other limitations in paper I was the small number of included 
patients and that no interobserver analyses were performed. Quantification of CEUS-
derived perfusion holds several limitations which are further discussed in the 
following paragraphs.  
 
In paper II and III, the primary investigator gained more experience during the 
inclusion period, which could affect the validity of the results. Still, all ultrasound 
examinations were under close supervision by experienced sonographers during the 
first months of inclusion. Thereafter, a second observer re-examined a randomly 
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selected subgroup of patients for interobserver assessment.  
 
5.2 Discussion of the main results  
5.2.1 Clinical and biochemical evaluation of disease activity  
Clinical and biochemical markers seem appealing for monitoring activity as they are 
simple, non-invasive, and have low operator dependency. Although well-established 
and valuable in the clinic, clinical symptoms and CRP have limited reliability for 
assessing inflammatory activity in CD (49, 54). This was further clearly demonstrated 
in paper II and III, as these parameters yielded poor accuracy for separating patients 
in remission from activity and had poor correlation with endoscopic activity.  
Fecal calprotectin is useful for initial work-up and follow-up examinations (17, 42). 
Still, it is probably better suited for evaluating distal inflammation, as seen in 
ulcerative colitis (54) and colonic CD (60). In paper II and III, we found poor 
sensitivity and only moderate correlation to endoscopy. Similar correlations between 
endoscopy and clinical- and biochemical tests are previously reported (50). By 
excluding patients with terminal ileitis, the diagnostic accuracy significantly 
improved. Thus, our findings confirm that calprotectin is better suited for evaluating 
activity in patients with colonic involvement. The ideal use of calprotectin in CD 
management is monitoring activity over time. Repeated samples from the same 
patients help identify changes in disease activity but patient reluctance for providing 
repeated samples (197, 198) limits its utility. This problem was clearly demonstrated 
in our studies, as patient compliance on delivering fecal samples was poor with 33-
40% missing data. There were no significant differences between the groups for 
delivering fecal samples. Furthermore, although conflicting evidence exits (199), 
previous studies report intra-individual variability of calprotectin (200, 201) which 
may further complicate interpretation. Ultimately, although being important non-
invasive tools in CD management, neither calprotectin nor CRP had sufficient 
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accuracy to predict endoscopic activity or remission and cannot replace 
ileocolonoscopic evaluation (50, 202). 
To overcome some of the practical challenges of fecal sampling, development and 
validation of a blood-based multi-marker test was recently performed (203). The 
authors found that the test could discriminate between active disease and remission, 
suggesting that the biomarker could replace some ileocolonoscopies. Still, most 
biomarkers constituting the test are not routinely measured. Moreover, as it cannot 
depict neither site nor extent, it must be complemented by additional methods.  
 
5.2.2 Ultrasonographic prediction of endoscopic activity 
In paper II and III, we found that increased bowel wall thickness (> 3 mm) has high 
diagnostic accuracy in distinguishing patients with active disease from patients in 
endoscopic remission in a heterogeneous hospital cohort.  
Although endoscopic remission is commonly considered as SES-CD of 0-2 (71), 
patients’ long-term prognosis seems to improve when there is no evidence of 
macroscopic inflammation defined as SES-CD or CDEIS scores of 0 (204, 205). This 
may be of particular importance in patients eligible for treatment discontinuation as 
the relapse rate seems to be less in patients obtaining endoscopic- rather than clinical 
remission after therapy withdrawal (206). Thus, in paper II, we used such strict 
endoscopic criteria (SES-CD=0) which have not been previously compared to 
ultrasonography.  
According to our data, GIUS seems to provide high sensitivity and positive predictive 
value for detecting inflammatory lesions and may be sufficient to evaluate disease 
activity in scenarios where continuation or escalation of treatment is appropriate. The 
diagnostic accuracy could be further improved by adding color Doppler on 
pathological bowel segments and fecal calprotectin in sonographic colitis. For 
patients eligible for treatment discontinuation, however, ultrasonography does not 
seem to provide sufficient accuracy as it is not sensitive enough to detect mild 
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inflammatory lesions and should thus be examined with ileocolonoscopy. 
Consequently, implementation of bowel ultrasound has the potential to reduce the 
number of ileocolonoscopic examinations, improving allocation of endoscopic 
resources, and lessen patients’ need to undergo invasive procedures. The upcoming 
national screening program for colorectal cancer will demand more endoscopy 
resources and may further push the development for endoscopic surrogate markers in 
IBD care.  
Our principal finding seems to be in concordance with other studies (131, 151, 163, 
207, 208), although there are some differences in design, ultrasound thresholds, and 
reference standard. Increased BWT due to inflammatory activity is considered the 
most important ultrasound parameter to detect active CD (126). Moreover, a recent 
study found that BWT was the best ultrasound parameter for measuring disease 
activity with good discriminative ability as well as a high correlation with SES-CD 
(r=0.60) (208), similar to our findings. By adding color Doppler, the positive 
predictive value increased, but we did not reveal adequate negative predictive value. 
These results are consistent with previous reports (151, 159), and could be due to 
insensitivity of equipment, obesity, or measuring at increased depths (125). A recent 
study suggests that further evaluations with CEUS may be useful to determine disease 
status when Doppler signals are lacking (151). Still, these measurements are usually 
performed on bowel segments with increased BWT, thus the pre-test probability for 
activity increases. Hence, measurements of BWT seems most suited to decide 
whether patients are in remission or not, while Doppler and CEUS are useful to 
quantify disease activity.  
 
Although increasing BWT correlates with disease severity (209), bowel wall 
thickening could also appear in fibrotic segments (210). Additional sonographic 
findings could be useful to distinguish between these entities; inflammatory segments 
could be depicted as loss of stratification, prominent submucosal layer, and increased 
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Doppler signals, while preserved stratification and thickened proper muscle layer 
suggests fibrosis (138, 139, 141, 151). In paper I, we found significantly thicker 
proper muscle and submucosal layers in the treatment failure group one and three 
months after treatment start, respectively. Such differences were not revealed for 
BWT which could be explained by a limited number of included study participants. 
Although reaching significance at one month only, a closer inspection of the proper 
muscle boxplots suggests that there were differences between the groups at treatment 
start and at three months as well. As a thickened proper muscle layer may be 
indicative of fibrosis (139), this could partly explain the lack of medical effect in our 
study. Furthermore, a thickened submucosal layer is associated with active CD (138, 
139, 211), which corresponds to our results. Thus, measurements of individual wall 
layers are simple and may provide additional guidance for disease activity evaluation. 
Although promising, their clinical significance is poorly investigated and should be 
examined in larger studies. Emerging methods such as CEUS (139, 164, 166) and 
elastography (212) may potentially aid further differentiation, although 
methodological challenges limit current use. 
  
Although the usefulness of ultrasonography is thoroughly demonstrated (132, 151, 
177), incorporation into clinical practice in Norway is limited. Ultrasound is 
commonly perceived as subjective and highly operator-dependent thus limiting its 
clinical utility. Although conflicting evidence exists (137), BWT measurements are 
found to have good reproducibility (136, 213), in line with our results. Recent 
recommendations regarding measurement standardization and minimum training may 
aid to standardize acquisition and interpretation of the US findings (125, 214).  
 
5.2.3 Ultrasonographic activity index to measure endoscopic activity  
A recent expert review advocates the use of cross-sectional imaging for monitoring 
CD patients (215). Although an MRI-based approach accurately depicts disease 
activity (86, 216), most protocols require bowel preparation and distention, as well as 
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administration of intravenous contrast agents. Gadolinium-based contrast agents may 
accumulate in brain tissue and should be limited, although no harmful effects are 
currently proven (217). Diffusion-weighted MRI or the simplified MaRIA score may 
overcome some of the obstacles of conventional MRI, as they are less time-
consuming and do not require administration of contrast agents (90, 218). Still, 
frequent use of MRI is limited due to the reduced availability and high costs.  
Ultrasonography seems well suited for systematic activity monitoring of CD patients, 
as it is rapid, non-invasive, well-tolerated by patients, and feasible in out-patient 
clinics (132, 177, 198). An accurate ultrasound score may ease interpretation of 
sonographic activity, thus facilitating incorporation in clinic. Moreover, as it is useful 
to monitor the same patient over time, an ultrasound score can determine whether the 
inflammatory activity increases or decreases. Several ultrasound activity indices have 
previously been developed (146-148, 219-221), but most with inadequate 
methodology (178).   
In paper III, we developed and validated a simple and reproducible ultrasound 
scoring system for Crohn’s disease, overcoming the limitations of previous scoring 
systems. The activity index, the Simple Ultrasound Score for Crohn’s Disease (SUS-
CD), correlates well with the SES-CD and may thus be a surrogate of endoscopic 
activity. The usefulness in daily life is further demonstrated, as real-world data with 
patients at different disease stages were included. 
 
Although BWT seems to be sufficient to distinguish between patients with active 
disease from patients in remission, it should be accompanied by additional 
sonographic parameters for quantifying activity. The SUS-CD was developed 
similarly as the SES-CD (66), using multiple linear regression to select the ultrasound 
parameters that should be included. Initially, seven sonographic parameters were 
carefully selected and weighted according to current knowledge (126). Length of the 
affected segment and stenosis were excluded due to multicollinearity and minimal 
unique contribution to the model, respectively. No case of fistula was present, and the 
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parameter was thus excluded. Although penetrating behavior indicates severe disease, 
the presence of fistulas or abscesses do not seem useful for score development as 
activity monitoring should be applicable in heterogeneous patient populations. 
The interobserver analysis of the development cohort revealed excellent agreement 
for BWT (ICC=0.91) and color Doppler (ICC=0.94), while it was poorer for 
stratification (ICC=0.60) and fatty wrapping (ICC=0.45). A recent international inter-
rater agreement study revealed similar findings where BWT (ICC=0.91) and color 
Doppler (κ=0.60) revealed good to excellent agreement, while stratification (κ=0.39) 
and fatty wrapping (κ=0.50) were less reproducible (213). These findings are in 
concordance with a previous Italian study (136). Still, poorer results are previously 
presented (137), highlighting the need for clear definitions and standardization of 
measurements. The high reproducibility of BWT and color Doppler could be due to 
their quantitative interpretation, while stratification and fatty wrapping are more 
subjective and thus more prone to different interpretations.  
The SUS-CD (Appendix V) was finally constituted by BWT and color Doppler as 
they provided significant contributions in predicting endoscopic activity and was easy 
to reproduce. These parameters are the most commonly selected in score 
development (178) and seem to be the best reflectors of disease activity. By 
excluding complications, length, stratification, and fatty wrapping, the ultrasound 
score lacks the ability of evaluating further important aspects of CD. However, the 
trade-off yields a reliable, reproducible, and easy-to-use tool during follow up. The 
excluded parameters may instead serve as additional modifiers when present. Further 
discussion regarding parameter selection, significance, and interpretation is provided 
in the associated paper. 
The ultrasound score seems well suited for monitoring CD activity, still, it is not 
developed for assessing proximal bowel segments, it may not be useful in patients 
with obesity or bowel gas, and does not seem to achieve sufficient sensitivity in 
detecting mild inflammatory lesions. Furthermore, increased BWT could occur in 
fibrotic segments as well, which could lead to misinterpretation. Thus, as the 
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ultrasound score may not be applicable in all patients, a careful selection of patients 
could be necessary. Also, it has not been tested for its ability to detect changes in 
disease activity. Although ultrasonography may not replace ileocolonoscopic 
examinations, it could serve as an adjunct. As it can be frequently performed, GIUS 
might facilitate close monitoring of disease activity and treatment response. 
Implementation of GIUS in clinic may potentially enable better allocation of 
endoscopic- and imaging resources. 
 
5.2.4 Predictive value of bowel perfusion in CD 
In paper I, we found that CEUS-derived bowel perfusion enables prediction of 
treatment outcome as there were significant differences between responders and non-
responders one month after treatment start. Increased bowel perfusion due to 
angiogenesis and dysfunctional regulation of blood supply are features of active CD 
(38, 39), and perfusion estimates may be potential surrogate markers. Our principal 
finding suggests that the efficacy of a treatment regime is poor in patients with 
sustained increased perfusion and that an early change in therapy could be beneficial. 
The current practice in our hospital is to assess the therapeutic outcome after three 
months of treatment start. Hence, implementation of CEUS may potentially 
accelerate treatment decisions, monitor treatment effect, decrease doctor’s delay, and 
enabling better tailoring of patient care. To our knowledge, this was the first study to 
report early perfusion differences with repeated CEUS-examinations during 12 
months of follow-up.  
All amplitude-based perfusion parameters except wash-out area under the curve and 
wash-in/ wash-out area under the curve were statistically significant one month after 
treatment start. However, with a closer examination of the boxplots, there seems to be 
a group effect and the non-significant results could be explained by type 2 errors. 
Moreover, the acquisition lasted for 60 seconds which might be insufficient to 
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evaluate the wash-out of contrast agents, and longer time recordings may be 
necessary. This was later demonstrated by Quaia et al. (167, 169) who found 
significant differences in all amplitude related parameters between responders and 
non-responders, when extending the contrast acquisition period to 120 seconds in 
larger patient cohorts (n=50 and n=115). In line with our results, they could neither 
find significant differences between time-related parameters.  
Our principal finding is in concordance with other studies (167-169, 222), even 
though there are differences in methodology. In our study, re-linearized bowel 
perfusion was normalized using the right iliac artery as an internal scaling factor. In 
contrast, other research groups evaluated the percentage change between perfusion at 
baseline and follow-up without using a scaling factor (167, 169, 223), measured 
video intensity in greyscale on log-compressed recordings (222), or assessed the pre-
post difference in contrast enhancement on the same recording on log-compressed 
video data (168). Measurements of contrast intensity in decibel may be another 
method useful in clinic (161) although linear intensity data is the only mathematically 
valid approach for perfusion calculation (115).  
Beyond the differences in methods and numerical values, all aforementioned studies 
reached similar conclusions. There are, however, serious concerns regarding 
reproducibility which could be partly due to vendor-specific detection of 
microbubbles and difficulties in obtaining raw-data (116, 224, 225), as well as inter-
individual differences in the arterial input function (AIF). Thus, both the 
quantification method as well as the US machine- and settings must be identical in 
follow-up examinations. The AIF describes the input of contrast agents to the tissue 
of interest and is substantially influenced by injection speed and inter-individual 
differences in size, vascular system, and physiology (111, 226, 227). The AIF could 
be estimated using a complex mathematical model, as proposed by Jirik et al., 
enabling calculation of absolute perfusion (mL/min) (111). 
As different ultrasound systems measure contrast signals differently, the comparison 
between various US vendors becomes difficult (228). Application of a calibration 
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procedure using phantoms (224) or by measuring absolute perfusion (111) may 
overcome these challenges. Furthermore, the size and selection of the region of 
interest could significantly influence the result, suggesting that strict criteria are 
needed (229). To facilitate implementation of CEUS in treatment monitoring, an 
international consensus regarding standardization of acquisition, perfusion 
quantification, and software selection is warranted. 
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6. Conclusion  
We demonstrated that gastrointestinal ultrasound could accurately quantify 
inflammatory activity in CD. We developed and validated a simple ultrasound 
activity index that correlates well with ileocolonoscopy and has low interobserver 
variability. We have also provided evidence for the ability of ultrasonography to 
accurately differentiate between patients with disease activity from patients in 
endoscopic remission. Bowel wall thickness exceeding 3 mm is a simple and 
reproducible cut-off value, providing sufficient discriminative ability. Thus, 
implementation of ultrasonography in outpatient clinics could significantly impact 
clinical decision making. Furthermore, by adding ultrasound contrast agents, we 
demonstrated the ability of ultrasonography to provide prognostic information 
regarding treatment effect, as there were perfusion differences between medical 
responders and non-responders. Still, challenges remain before CEUS could be 










7. Future perspectives  
Ileocolonoscopy will still be necessary in the management of CD patients but has 
limitations that restrict its use. Implementation of ultrasonography during follow-up 
could reduce the need for ileocolonoscopic examinations, enabling better allocation 
of endoscopic resources. Future studies or expert recommendations should further 
designate dedicated scenarios where ultrasonography may be appropriate, and further 
clarify which should be reserved for other modalities.  
We developed an ultrasound activity index (SUS-CD) that correlates well with 
endoscopy and may ease interpretation of ultrasonographic disease activity. Still, the 
scoring system should be validated by other groups and tested for responsiveness to 
changes in disease activity before incorporation in clinical practice. Future studies 
may further investigate the ability of the SUS-CD to guide treatment decisions. The 
clinical significance of transmural healing is uncertain, although it may represent a 
profound level of healing. This could be further clarified in large prospective studies 
including MRI, ultrasound, and ileocolonoscopy.  
Point-of-care-ultrasonography (POCUS) allows for rapid diagnosis at the bedside and 
has emerged as a valuable tool in the emergency department. In bowel ultrasound, 
POCUS is an evolving concept and still in its infancy. As BWT is simple, 
reproducible, and highly accurate to discriminate between active and inactive bowel 
segments, it may provide clinicians with additional guidance in point-of-care settings 
at the out-patient clinic, and should be further investigated in future studies  
Contrast-enhanced ultrasound has an emerging role in CD management. However, 
there is high variability in detection and quantification of contrast agents, making 
standardization and interpretation of perfusion measurements difficult. Thus, 
standardization, simplification, and improvement of software and quantification 
procedure are needed. Moreover, a comparison of different quantification procedures 
ultimately selecting the most appropriate in daily clinical practice should be 
performed. Finally, 3- and 4D ultrasound may overcome some challenges of CEUS, 
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including out-of-plane images, difficulties in motion correction, and assessment of 
absolute perfusion.  
Many CD patients suffer due to impaired bowel function. The need for frequent 
invasive investigations adds to the patients’ burden. Broader implementation of 
ultrasound as a disease monitoring tool may aid clinicians to perform better tailoring 
of patient care as well as alleviating patient’s burdens.  
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Montreal classification  
 Montreal Classification 
Age at diagnosis  
<16 years A1 
17-40 years A2  
>40 years A3  
  
Disease location  
Ileal disease L1 
Colonic disease L2 
Ileocolonic disease L3 
Isolated upper disease* L4 
  
Disease behavior   
Non‐stricturing and non‐penetrating B1 
Stricturing B2 
Penetrating B3 
Perianal disease modifier† p 
 
*L4 is a modifier that can be added to L1–L3 when concomitant upper 
gastrointestinal disease is present. 

















Crohn’s Disease Activity Index 
All factors relate to the last seven days before the exam.  
Category Weighting factor Subtotal 
Number of liquid or soft stools in 7 days x2  






General well-being, sum of 7 daily 
ratings 
0=well,  
1=slightly below par,  
2=poor,  
3=very poor,  
4=terrible 
x7  
Number of listed complications (One 
point for each) 
• arthritis or arthralgia  
• iritis or uveitis 
• erythema nodsosum, pyderma 
gangernosum or apththous 
stomatitis 
• anal fissure, fistula or perirectal 
abscess 
• Other fistulas 
• Fever (>37,8 degrees Celcius) 
x20  
Use of drug to reduce diarrhoea?  
0=No, 
1=Yes   
x30  


















Final Score (add subtotals)           
 
Interpretation: 
Remission:  CDAI <150 
Mild:   CDAI 150-219 
Moderate:  CDAI 220-450 















Harvey-Bradshaw Index of Crohn’s Disease 
Responses should be based on the 24-hour period preceding the visit 
Category Subtotals 
General Wellbeing 
0 = Very Well   3 = Very Poor  
1 = Slightly Below Par  4 = Terrible 
2 = Poor 
 
Abdominal Pain 
0 = None              2 = Moderate    
1 = Mild    3 = Severe 
 




0 = None   2 = Definite  
1 = Dubious   3 = Definite and Tender 
 
Extra-intestinal  manifestations of CD (score 1 per item) 
☐ Arthralgia/Arthritis 
☐ Uveitis/Iritis 
☐ Erythema nodosum 
☐ Apthous ulcers 
☐ Pyoderma gangrenosum 
☐ Anal fissure 
☐ Draining fistula (eg, perianal, enterocutaneous, rectovaginal) 
☐ Perianal Abscess 
 




Remission:  HBI <5 
Mild:   HBI 5-7 
Moderate:  HBI 8-16 






Simple endoscopic activity score for Crohn’s Disease (SES-CD)  




Left colon Rectum Total 
Ulcer size (0-3)       
Ulcerated surface 
(0-3) 
      
Affected surface (0-
3) 
      
Stenosis  
(0-3) 
      








Remission:  SES-CD 0-2 
Mild:   SES-CD 3-6 
Moderate:  SES-CD 7-15 
Severe: SES-CD ≥16 
 
 
Variables 0 1 2 3 








None <10% 10-30% >30% 
Affected 
surface 
Unaffected <50% 50-75% >75% 





Definitions of variables eligible for the ultrasound index: 




<3.0 mm 3.0-4.9 mm or 
4.0-4.9 mm 
(rectum) 
5.0-7.9 mm ≥8.0 mm 















No affection <5 cm 5-10 cm >10 cm 
Color Doppler 
score  
No or single 
vessel 
2-5 vessels per 
cm2 
>5 vessels per 
cm2 
 
Stratification Normal Focal loss Diffuse loss  
Fatty wrapping Absent  Present   
Fistula Absent Present   
 
 
Simple ultrasound score of Crohn’s Disease (SUS-CD)  










      
Color Doppler 
score (0-2) 
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